Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(170 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(86 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(78 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(27 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1375 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Cor e Forma:SolidPeso molecular:901.42TL02-59
CAS:<p>TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.</p>Fórmula:C32H34F3N5O4Pureza:98.77%Cor e Forma:SolidPeso molecular:609.64EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Cor e Forma:SolidPeso molecular:538.64Vepafestinib
CAS:<p>Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].</p>Fórmula:C26H30N6O3Pureza:98.56%Cor e Forma:SolidPeso molecular:474.55OTS447
CAS:<p>OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .</p>Fórmula:C27H32ClN3O2Pureza:98.78%Cor e Forma:SolidPeso molecular:466.02FGFR3-IN-6
CAS:<p>FGFR3-IN-6 is a potent, selective inhibitor of FGFR 3, exhibiting an IC50 value of less than 350 nM , and is utilized in cancer research [1].</p>Fórmula:C25H23FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:486.5Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Fórmula:C20H16FN5O2Pureza:99.77%Cor e Forma:SolidPeso molecular:377.37c-Fms-IN-14
CAS:<p>c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].</p>Fórmula:C26H24N6OPureza:98%Cor e Forma:SolidPeso molecular:436.51DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:547.56UniPR1447
CAS:<p>UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].</p>Fórmula:C36H50N2O4Pureza:98%Cor e Forma:SolidPeso molecular:574.79UniPR505
CAS:<p>UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.</p>Fórmula:C39H57N3O5Pureza:98.23%Cor e Forma:SolidPeso molecular:647.89EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Cor e Forma:SolidPeso molecular:266.29BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Fórmula:C27H32N8O3Pureza:97.26%Cor e Forma:SolidPeso molecular:516.6BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Cor e Forma:SolidPeso molecular:354.2FGFR4-IN-16
CAS:<p>FGFR4-IN-16 (CY-15-2) is a covalent inhibitor targeting FGFR-4, utilized in cancer research [1].</p>Fórmula:C35H30Cl2N6O5Pureza:98%Cor e Forma:SolidPeso molecular:685.56KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Cor e Forma:SolidPeso molecular:555.03TRK-IN-24
CAS:<p>TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,</p>Fórmula:C39H45N7O3Pureza:98%Cor e Forma:SolidPeso molecular:659.82TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Fórmula:C26H27Cl2N5O2Pureza:98%Cor e Forma:SolidPeso molecular:512.43JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Cor e Forma:SolidPeso molecular:488.35FGFR4-IN-8
CAS:<p>FGFR4-IN-8 is a selective, ATP-competitive FGFR4 inhibitor with IC50s as low as 0.25 nM, halting growth of Hep3B cells at 29 nM and showing in vivo efficacy.</p>Fórmula:C32H34Cl2FN7O3Pureza:98%Cor e Forma:SolidPeso molecular:654.56EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Fórmula:C33H37ClN8O3Pureza:98%Cor e Forma:SolidPeso molecular:629.15EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Fórmula:C26H30N8O2Pureza:98%Cor e Forma:SolidPeso molecular:486.57Type II TRK inhibitor 1
CAS:<p>Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.</p>Fórmula:C35H33F3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:670.68FGFR-IN-11
CAS:<p>FGFR-IN-11 (compound I-5) is an orally active, covalent inhibitor of FGFR, exhibiting IC50 values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (</p>Fórmula:C28H29ClN4O4Pureza:98%Cor e Forma:SolidPeso molecular:521.01ENT-C225
CAS:<p>ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.</p>Fórmula:C26H40N4O5Pureza:99.36% - 99.36%Cor e Forma:SolidPeso molecular:488.62EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Fórmula:C54H54Cl2FN7O7S2Pureza:98%Cor e Forma:SolidPeso molecular:1067.08Tyrosine kinase-IN-6
CAS:<p>Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].</p>Fórmula:C37H31F2N5O5SPureza:98%Cor e Forma:SolidPeso molecular:695.732′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Fórmula:C10H13N5O3SPureza:98%Cor e Forma:SolidPeso molecular:283.31EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Fórmula:C23H15ClFN3OS2Pureza:98.93%Cor e Forma:SolidPeso molecular:467.97Ropsacitinib
CAS:<p>Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).</p>Fórmula:C20H17N9Pureza:99.87%Cor e Forma:SolidPeso molecular:383.41CH6953755
CAS:<p>CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.</p>Fórmula:C26H22F2N6O4SPureza:98.03%Cor e Forma:SolidPeso molecular:552.55TAK-020
CAS:<p>TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.</p>Fórmula:C18H17N5O3Pureza:98.79%Cor e Forma:SolidPeso molecular:351.36WAY-600
CAS:<p>WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308).</p>Fórmula:C28H30N8OPureza:99.88%Cor e Forma:SolidPeso molecular:494.59ALK-IN-27
CAS:<p>Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.</p>Fórmula:C23H22ClFN6OPureza:99.71%Cor e Forma:SolidPeso molecular:452.91MK-2461
CAS:<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Fórmula:C24H25N5O5SPureza:95.41% - 99.53%Cor e Forma:SolidPeso molecular:495.55EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Fórmula:C28H31ClN6O4Pureza:99.16%Cor e Forma:SolidPeso molecular:551.04BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Fórmula:C24H23FN8O2Pureza:98.24% - 98.91%Cor e Forma:SolidPeso molecular:474.49EGFR-IN-87
CAS:<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Fórmula:C28H33N7O2Pureza:98.64%Cor e Forma:SolidPeso molecular:499.61Tyrphostin AG 538
CAS:<p>Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.</p>Fórmula:C16H11NO5Pureza:98.75%Cor e Forma:SoildPeso molecular:297.26Zidesamtinib
CAS:<p>Zidesamtinib (NVL-520) is a ROS1 fusion and resistance mutation inhibitor that inhibits ROS1 and can be used to study non-small cell lung cancer.</p>Fórmula:C22H22FN7OPureza:99.74%Cor e Forma:SolidPeso molecular:419.455FIIN-1
CAS:<p>FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3,</p>Fórmula:C32H39Cl2N7O4Pureza:98.75%Cor e Forma:SolidPeso molecular:656.6Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Fórmula:C24H25ClN4O5Pureza:99.81%Cor e Forma:SolidPeso molecular:484.93BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Fórmula:C24H31N5O4Pureza:96.74%Cor e Forma:SolidPeso molecular:453.53Src Inhibitor 3
CAS:<p>Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.</p>Fórmula:C34H32ClFN8O4Pureza:98.35%Cor e Forma:SolidPeso molecular:671.12EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Cor e Forma:SolidPeso molecular:662.02AZ-23
CAS:<p>AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.</p>Fórmula:C17H19ClFN7OPureza:99.4%Cor e Forma:SolidPeso molecular:391.83PF-06273340
CAS:<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Fórmula:C23H22ClN7O3Pureza:98% - 98.00%Cor e Forma:SolidPeso molecular:479.92TrkA-IN-8
CAS:<p>TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.</p>Fórmula:C20H16N4Cor e Forma:SolidPeso molecular:312.368IGF-1R inhibitor-4
CAS:<p>IGF-1Rinhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, demonstrating an inhibition rate of 63% at a concentration of 10 μM. This compound plays a significant role in cancer research.</p>Fórmula:C13H15ClN4OCor e Forma:SolidPeso molecular:278.737
